

increased resistance of said cells, relative to cells from a wild type pig, to be lysed by human serum.

64. Cells isolated from the pig of claim 62, wherein said cells lack the GAL epitope as determined by the failure of said cells to bind anti-GAL antibodies and IB4 lectin, and by the increased resistance of said cells, relative to cells from a wild type pig, to be lysed by human serum.

65. A cell line established from the cells of claim 63.

66. A cell line established from the cells of claim 64.

67. A porcine cell comprising at least one inactivated α -1,3 galactosyltransferase gene.

REMARKS

Claims 4-7, 12, 15-18, 21-26, 28-29, and 31 have been canceled. Claims 8-11, 13-14, 19-20, 27, 30 and 32-45 were canceled in a first Preliminary Amendment submitted December 4, 1997. Claims 1-3 and new claims 46-67 remain for consideration. Support for the new claims, which reflect language suggested by the Examiner in parent application Serial No. 08/378,617, is found in the originally submitted claims and throughout the specification. Support for the term "oocyte" in new claim 59 is found in the specification, page 86 (EXAMPLE 10, part D).

Amendments to the Sequence Listing, included in the substitute sheets and substitute copy of the computer readable form of the Sequence Listing, have been made in accordance with 37 CFR 1.825 (a) and (b) to correct minor errors in the porcine α -1,3 galactosyltransferase nucleic acid (SEQ ID NO:7) and amino acid (SEQ ID NO:10) sequences. The substitute copy in computer

readable form is the same as the substitute sheets of the Sequence Listing.


These errors were first disclosed in an October 16, 1995 Information Disclosure Statement in parent application Serial No. 08/378,617, and are again disclosed in an Information Disclosure Statement submitted herewith. The attached copy of a declaration from Dr. Robert Crawford, submitted in the parent application, describes that the sequencing errors arose through difficulties in reading the original sequencing gel and through a clerical mistake. No new matter is introduced by these amendments.

Substitute Figures 4 and 5 have been submitted to reflect the minor sequence amendments to the porcine α -1,3 galactosyltransferase nucleic acid and amino acid sequences discussed above. No new matter is introduced by this substitution of revised Figures.

Please apply any charges not covered, or any credits, to Deposit Account 06-1050.

Respectfully submitted,

Date: April 10, 1998


Mark S. Ellinger, M.D.
Reg. No. 34,812

Fish & Richardson P.C., P.A.
60 South Sixth Street, Suite 3300
Minneapolis, MN 55402

Telephone: 612/335-5070
Facsimile: 612/288-9696
11763.M11